Notes forming part of the financial statements
4. SHARE-BASED PAYMENTS
Equity settled awards
In July 2015, the Group established an equity settled Executive Share Option Scheme (ESOS 2015) under which options to purchase shares in C&C Group plc are granted to certain executive Directors and members of management. Under the terms of the scheme, the options are exercisable at the market price prevailing at the date of the grant of the option.
Options were granted in May 2016, June 2017, November 2017 and May 2018 under this scheme. The vesting of these awards is based on compound annual growth in underlying EPS over a three year performance period, commencing in the financial year when an award is granted. If compound annual growth in underlying EPS over the performance period is 3% per annum with respect to the May 2016 awards or 2% per annum for all awards thereafter, then 25% of the awards vest. If the compound annual growth in underlying EPS over the performance period is 6% per annum then 100% of the awards vest. There is straight-line vesting between both points and no reward for below threshold performance. Options granted in May 2016 were deemed to have partially achieved their performance conditions and consequently 65.4% vested. Options granted in 2017 have achieved their performance conditions and therefore vest in full.
In July 2015, the Group established a Long-Term Incentive Plan (Part I) (LTIP 2015 (Part I)) under the terms of which options to purchase shares in C&C Group plc are granted at nominal cost to certain executive Directors and members of management. Options have been granted under this scheme since May 2016. All such awards granted are subject to the following three performance conditions:
- 33% of the award is subject to compound annual growth in underlying EPS over the three year performance period. If compound annual growth in underlying EPS over the performance period is 3% per annum then 25% of the awards vest. If the compound annual growth in underlying EPS over the performance period is 8% per annum then 100% of the awards vest.
- 33% of the award is subject to the performance condition that the Free Cash Flow Conversion ratio (‘FCF’) of the Group (excluding the impact of exceptional items) would be 65% conversion, over the three year performance period, at which case 25% of this element of the award would vest. If the FCF was 75% then 100% of this element of the award would vest.
- 33% of the award is subject to a Return on Capital Employed (‘ROCE’) target. If the ROCE is 9.3% then 25% of this element of the award would vest. If the ROCE was 10% then 100% of this element of the award would vest.
In all three components of the performance conditions of the LTIP 2015 (Part I) there is straight-line vesting between both points and no reward for below threshold performance. Options granted in May 2016 were deemed to have partially achieved their performance conditions and consequently 62.4% vested. Options granted in 2017 have achieved their performance conditions and therefore vest in full.
If awards are made to an individual under both the ESOS 2015 and the LTIP 2015 (Part I) in respect of the same financial year the overall maximum award, other than in exceptional circumstances, will be capped at 250% of salary. In exceptional circumstances the maximum combined ESOS 2015 and LTIP 2015 (Part I) award in respect of any financial year is 500% of salary.
In June 2010, the Group established a Recruitment and Retention Plan (“R&R”) under the terms of which options to purchase shares in C&C Group plc at nominal cost are granted to certain members of management, excluding executive Directors.
The performance conditions and/or other terms and conditions for awards granted under this plan are specifically approved by the Board of Directors at the time of each individual award, following a recommendation by the Remuneration Committee. Performance conditions vary per award but include, some or all, of the following conditions; continuous employment, performance targets linked to the business unit to which the recipient is aligned or a requirement to have a personal shareholding of the Company stock at the end of the performance period.
Obligations arising under the Recruitment and Retention Plan will be satisfied by the purchase of existing shares on the open market. On settlement, any difference between the amount included in the Share-based payment reserve account and the cash paid to purchase the shares is recognised in retained income via the Statement of Changes in Equity.
In February 2019, the Group established a Deferred Bonus Plan (“DFP”) under the terms of which options to purchase shares in C&C Group plc at nominal cost are granted to certain members of management.
In the prior year, 13,513 awards were granted in February 2019 under the DFP. Awards are subject to a continuous employment performance condition only, and if achieved, will vest in February 2021.
In November 2011, the Group set up Partnership and Matching Share Schemes for all ROI and UK based employees of the Group under the approved profit sharing schemes referred to below. Under these schemes, employees can invest in shares in C&C Group plc (partnership shares) that will be matched on a 1:1 basis by the Company (“matching shares”) subject to Revenue approved limits. Both the partnership and matching shares are held on behalf of the employee by the Scheme trustee, Link Group Limited (previously Capita Corporate Trustees Limited). The shares are purchased on the open market on a monthly basis at the market price prevailing at the date of purchase with any remaining cash amounts carried forward and used in the next share purchase. The shares are held in trust for the participating employee, who has full voting rights and dividend entitlements on both partnership and matching shares. Matching shares may be forfeited and/or tax penalties may apply if the employee leaves the Group or removes their partnership shares within the Revenue-stipulated vesting period. The Revenue stipulated vesting period for matching shares awarded under the ROI scheme is three years and under the UK scheme is five years.
The Group held 298,016 matching shares (596,032 partnership and matching) in trust at 29 February 2020 (2019: 266,632 matching shares (533,264 partnership and matching shares held)).
In the current financial year the Group, recognising that some employees of Matthew Clark and Bibendum (“MCB”), which the Group acquired in the prior financial year, had previously lost money in a share scheme operated by the previous owners of MCB and prior to MCB being acquired by the Group, committed to allocating to those employees, C&C Group plc shares in May 2021, equivalent in value to the amount they had lost in the share scheme of the previous owners of MCB. The employees must also be investing in the Group’s partnership and matching share scheme to qualify for the award.
Award valuation
The fair values assigned to the equity settled awards granted were computed in accordance with a Black Scholes valuation methodology.
As per IFRS 2 Share-based Payment, non-market or performance related conditions were not taken into account in establishing the fair value of equity instruments granted, instead these non-market vesting conditions are taken into account by adjusting the number of equity instruments included in the measurement of the transaction amount so that, ultimately the amount recognised for time and services received as consideration for the equity instruments granted is based on the number of equity instruments that eventually vest, unless the failure to vest is due to failure to meet a market condition.
The main assumptions used in the valuations for equity settled share-based payment awards granted in the current and prior financial years were as follows:-
LTIP options granted Dec 19 | LTIP options granted May 19 | R&R options granted Dec 19 | R&R options granted Feb 20 | DBP options granted Feb 19 | R&R options granted Feb 19 | R&R options granted Feb 19 | R&R options granted Jun 18 | LTIP options granted Feb 19 | LTIP options granted Jan19 | LTIP options granted May 18 | ESOS options granted May 18 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fair value at date of grant | €4.66 | €3.71 | €4.27 | €4.17 | €3.05 | €2.64 | €2.77 | €2.908 | €3.05 | €3.30 | €2.99 | €0.255 |
Exercise price | - | - | - | - | - | - | - | - | - | - | - | €2.99 |
Risk free interest rate | 0.63% | 0.63% | 0.63% | 0.55% | 0.76% | 0.78% | 0.76% | 0.51% | - | - | - | 0.65% |
Expected volatility | 24.9% | 24.5% | 24.9% | 25.3% | 25.0% | 23.15% | 22.89% | 21.77% | - | - | - | 21.44% |
Expected term until exercise –years | 2.5 | 5 | 2.5 | 2.3 | 2 | 3 | 2 | 1 | 3 | 5 | 3 | 3 |
Dividend yield | - | - | 3.40% | 3.57% | - | 4.82% | 4.82% | 4.78% | - | - | - | 4.88% |
Expected volatility is calculated by reference to historic share price movements prior to the date of grant over a period of time commensurate with the expected term until exercise. The dividends which would be paid on a share reduces the fair value of an award since, in not owning the underlying shares, a recipient does not receive the dividend income on these shares. For LTIP 2015 (Part I) awards, the participants are entitled to receive dividends, and therefore the dividend yield has been set to zero to reflect this.
Details of the share entitlements and share options granted under these schemes together with the share option expense are as follows:-
Grant date | Vesting period | Number of options/ equity Interests granted | Number outstanding at 29 February 2020 | Grant price | Market value at date of grant | Fair value at date of grant | Expense / (income) in Income Statement 2020 | 2019 |
---|---|---|---|---|---|---|---|---|
€ | € | € | €m | €m | ||||
Executive Share Option Scheme (ESOS 2015) | ||||||||
12 May 2016 | 3 years | 593,700 | 175,492 | 4.18 | 4.041 | 0.4245 | - | - |
1 June 2017 | 3 years | 830,702 | 558,844 | 3.40 | 3.364 | 0.328 | 0.1 | 0.1 |
13 November 2017 | 3 years | 246,211 | 246,211 | 2.93 | 2.880 | 0.219 | - | - |
31 May 2018 | 3 years | 939,466 | 472,398 | 2.99 | 2.99 | 0.255 | - | 0.1 |
Long-Term Incentive Plan 2015 (Part I) | ||||||||
12 May 2016 | 3 years | 395,800 | 111,806 | - | 4.041 | 4.041 | - | 0.1 |
1 June 2017 | 3 years | 553,799 | 372,561 | - | 3.364 | 3.364 | 0.4 | 0.4 |
1 August 2017 | 3 years | 494,646 | 324,182 | - | 3.069 | 3.069 | 0.1 | 0.5 |
13 November 2017 | 3 years | 164,140 | 164,140 | - | 2.880 | 2.880 | 0.2 | 0.2 |
31 May 2018 | 3 years | 626,311 | 314,932 | - | 2.990 | 2.990 | 0.1 | 0.5 |
11 February 2019 | 3 years | 478,343 | 395,763 | - | 3.05 | 3.05 | 0.4 | - |
23 May 2019 | 3 years | 605,249 | 335,216 | - | 3.71 | 3.71 | 0.3 | - |
12 December 2019 | 3 years | 293,961 | 293,961 | - | 4.66 | 4.66 | 0.1 | - |
Recruitment & Retention Plan | ||||||||
21 May 2014 | 1 – 3 years | 823,233 | 15,391 | - | 4.34 | 1.91 – 4.19 | - | - |
30 October 2015 | 2 years | 490,387 | 22,915 | - | 3.60 | 3.27 – 3.53 | - | - |
12 May 2016 | 1.5 – 2.5 years | 193,817 | 2,775 | - | 4.041 | 3.71 – 3.84 | - | - |
1 August 2017 | 1.8 years | 64,469 | 16,636 | - | 2.8172 | 2.8172 | - | - |
11 February 2019 | 2 – 3 years | 448,936 | 448,936 | - | 3.05 | 2.64 – 2.77 | 0.4 | - |
12 December 2019 | 2.5 years | 446,081 | 446,081 | - | 4.66 | 4.27 | 0.2 | - |
18 February 2020 | 2 years | 56,383 | 56,383 | - | 4.52 | 4.17 | - | - |
Deferred Bonus Plan | ||||||||
11 February 2019 | 2 years | 13,513 | 13,513 | - | 3.05 | 3.05 | - | - |
8,759,147 | 4,788,136 | 2.3 | 1.9 | |||||
MCB compensation awards | 0.2 | - | ||||||
2.5 | 1.9 | |||||||
Partnership and Matching Share Schemes | 596,032* | 0.3 | 0.2 |
* Includes both partnership and matching shares.
The amount charged to the Income Statement includes a credit of €0.5m (2019: €nil), being the reversal of previously expensed charges on equity settled option schemes where the non-market performance conditions were deemed no longer likely to be achieved or the employee has left the Company.
A summary of activity under the Group’s equity settled share option schemes with the weighted average exercise price of the share options is as follows:-
2020 | 2019 | |||
---|---|---|---|---|
Number of options/ equity Interests | Weighted average exercise price | Number of options/ equity Interests | Weighted average exercise price | |
€ | € | |||
Outstanding at beginning of year | 5,491,198 | 1.33 | 3,250,587 | 1.39 |
Granted/correction to opening balance | 1,415,187 | - | 2,708,599 | 1.04 |
Exercised | (259,166) | 1.40 | (64,445) | - |
Forfeited/lapsed | (1,859,083) | 1.16 | (403,543) | - |
Outstanding at end of year | 4,788,136 | 1.00 | 5,491,198 | 1.33 |
The aggregate number of share options/equity Interests exercisable at 29 February 2020 was 345,015 (2019: 113,045).
The unvested share options/equity Interests outstanding at 29 February 2020 have a weighted average vesting period outstanding of 1.3 years (2019: 1.8 years). The weighted average contractual life outstanding of vested and unvested share options/equity Interests is 7.1 years (2019: 7.5 years).
The weighted average market share price at date of exercise of all share options/equity Interests exercised during the year was €4.39 (2019: €3.11); the average share price for the year was €4.03 (2019: €3.17); and the market share price as at 29 February 2020 was £3.28 or €3.84 euro equivalent (28 February 2019: €3.06 or £2.63 sterling equivalent).